MedPage Today

FDA Greenlights Imaging Agent to Detect Residual Cancer After Lumpectomy

The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...
Southeast Missourian

New radiation treatment for post-lumpectomy patients is faster, easier

Breast cancer is hard enough. Treatment should be quick and easy. That's the thinking of many physicians who have opted to offer MammoSite, a type of radiation that cuts treatment time from several ...
Business Wire

Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer

NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today ...
ascopubs.org

Assessing the marginal costs of radiation therapy and antiestrogen therapy for post-lumpectomy, early-stage breast cancer across Medicaid and Medicare plans.

Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...
ascopubs.org

Utilization of post-lumpectomy radiation therapy in women 70 years of age or older: A report from the National Cancer Data Base.

Impact of surgery and radiation of the primary among women with de novo stage IV breast cancer. Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and ...